Drawing for SRYSATA

USPTO serial 79236512

SRYSATA

Reviewed by CopyMark Law Group

Reg. 5614189Status 404
Filing date
Status date
Registration date
Nov 27, 2018
Examiner
OSGOOD, KRYSTINA E
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SRYSATA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 8, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 9, 2022GPNXNOTIFICATION PROCESSED BY IB—
May 23, 2022GPNXNOTIFICATION PROCESSED BY IB—
Feb 20, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Feb 20, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 1, 2019GPNXNOTIFICATION PROCESSED BY IB—
Jan 12, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 11, 2019FIMPFINAL DISPOSITION PROCESSED—
Dec 27, 2018GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Nov 27, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 2, 2018GPNXNOTIFICATION PROCESSED BY IB—
Sep 11, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 5, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 5, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 22, 2018NPUBNOTICE OF PUBLICATION—
Aug 6, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 2, 2018DOCKASSIGNED TO EXAMINER—
Jul 24, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 18, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 16, 2018LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jul 12, 2018SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance